Danaher Corporation (NYSE: DHR) , a global science and technology innovator, has recently been the subject of heightened investor attention following two significant announcements that collectively paint a picture of a company executing a disciplined capital allocation strategy. While rewarding shareholders with a consistent return of capital, Danaher is simultaneously making a bold, multi-billion dollar bet to solidify its leadership in the diagnostics space. These developments invite a closer examination of where the industrial and healthcare conglomerate is headed in the near and long term. Returning Value to Shareholders: The Quarterly Dividend First, in a move that underscores its commitment to providing tangible returns to its investors, Danaher announced on February 24 that its Board of Directors had approved a regular quarterly cash dividend of $0.40 per share of its common stock. This upcoming distribution is scheduled to be paid on April 24, 2026, to all shareholders of record as of the close of business on March 27, 2026. This declaration is consistent with Danaher's history as a reliable dividend payer. The company has established a track record of not only maintaining but steadily increasing its dividend over time, reflecting the strength of its diversified business model and its capacity to generate substantial, recurring free cash flow. For income-oriented investors, this regular payout provides a measure of stability and confidence, even as the company pursues larger strategic initiatives. A Transformative Acquisition: The $9.9 Billion Masimo Deal Just one week prior to the dividend announcement, on February 17, Danaher unveiled its most ambitious strategic move in recent memory: a definitive agreement to acquire Masimo Corporation. Masimo is widely recognized as a leading, specialized provider of innovative noninvasive patient monitoring technologies. The company is particularly renowned for its advanced pulse oximetry solutions, as well as a broader portfolio of patient monitoring devices and sensors, with its primary market focus being acute care settings such as hospitals and intensive care units. The financial terms of the agreement are substantial. Danaher will acquire all outstanding shares of Masimo common stock for $180 per share in cash. This translates to a total enterprise value of approximately $9.9 billion , a figure that includes the assumption of Masimo's existing indebtedness and is net of any acquired cash. From a valuation perspective, Danaher's management has provided context for the deal's financial logic. They stated that the acquisition price represents a transaction multiple of roughly 18 times Masimo's estimated EBITDA for the full year 2027. However, when incorporating the full run-rate impact of expected annual cost synergies—efficiencies gained by combining operations, leveraging scale, and integrating functions—the effective multiple compresses to a more attractive 15 times the estimated 2027 EBITDA. This suggests that management sees a clear and actionable path to extracting value from the combination, making the premium price justifiable. Strategic Integration and Portfolio Synergy A critical element of the deal's structure is how Masimo will be integrated into the existing Danaher ecosystem. Upon completion of the transaction, Masimo is slated to operate as a standalone operating company within Danaher's Diagnostics segment. It will join a formidable and highly complementary portfolio of diagnostics leaders, including: Radiometer: A leader in acute care diagnostics, particularly blood gas analysis. Leica Biosystems: A provider of comprehensive workflows and automation for cancer diagnostics. Cepheid: A pioneer in rapid molecular diagnostics for infectious diseases. Beckman Coulter Diagnostics: A broad-based provider of clinical chemistry, immunoassay, and hematology systems for laboratories. This placement is highly strategic. Masimo's strength in noninvasive patient monitoring at the bedside directly complements Radiometer's leadership in acute care diagnostics. Together, they can offer a more comprehensive suite of technologies to hospital systems, from continuous monitoring to critical lab results. This synergy is expected to enhance Danaher's value proposition to healthcare providers, particularly in the high-acuity hospital environment. The Growth Trajectory and Danaher's Core Business Looking ahead, Danaher’s leadership has expressed strong confidence in Masimo's organic growth potential. The company has stated that Masimo is anticipated to deliver high-single-digit core revenue growth over the long term. This projected performance is not just an isolated benefit; it is expected to be additive enough to accelerate the core revenue growth profile of Danaher's entire Diagnostics segment. This is a crucial point, as it indicates that the acquisition is not merely about adding scale, but about enhancing the overall growth trajectory of one of the company's primary operating pillars. To fully appreciate this move, one must understand Danaher's broader business architecture. The corporation designs, manufactures, and markets a wide array of professional, medical, industrial, and commercial products and services. It is organized into four primary operating segments: Diagnostics: As highlighted, this segment offers a comprehensive range of clinical instruments, devices, consumables, reagents, and services used by hospitals, laboratories, and physicians to diagnose and treat diseases and other medical conditions. Biotechnology: This segment provides a vast portfolio of equipment, consumables, and software that enable the research, development, and commercial production of biological medicines, including monoclonal antibodies and novel cell and gene therapies. Life Sciences: This segment offers an extensive suite of instruments and consumables used by researchers to study the fundamental biology of cells and molecules, accelerating the path to new discoveries. Environmental and Applied Solutions: This segment provides products and services that help protect critical water supplies and analyze and solve complex industrial and environmental challenges. Conclusion: A Dual-Pronged Strategy for Future Value In summary, Danaher Corporation (DHR) appears to be heading in a direction defined by a clear, dual-pronged strategy. On one hand, it maintains a disciplined approach to returning capital to shareholders through its reliable and growing quarterly dividend. On the other, it is aggressively deploying its balance sheet to acquire high-quality, high-growth assets like Masimo at a strategic price. By integrating Masimo into its Diagnostics segment, Danaher is not only adding a premier technology portfolio but is also positioning itself to capture greater share of the growing acute care and patient monitoring markets. For investors, the path ahead for Danaher looks to be one of continued portfolio optimization, synergistic growth, and a steadfast focus on its core mission of helping to realize the full potential of science and technology to improve human health.

1. RSI in oversold region 2. Price likely to rebound back to the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line) Notes: Maximum of 3 open positions

NYSE:DHR Q3 2025 Report HIGHLIGHTS EPS: $1.89, approximately 10% above the consensus estimate of $1.72 Biotechnology Segment: Grew 8.8% year-on-year, continuing its streak of quarterly growth Financials: Free cash flow for the quarter was $1.4 billion, with the operating profit margin increasing 40 basis points year-on-year to 27.9% Share Repurchase: The company repurchased 10 million shares for $2.01 billion. In September 2025, a new share repurchase program of up to 35 million shares was approved by the Board 2026 Guidance: Management provided its first guidance for 2026, expecting core revenue growth in the range of 3-6% and EPS growth. KEY DRIVERS 🔎

======= Volume ======= -slight decrease -stable ========== Price Action ========== - Bearish flag formed both long and short term ========= Oscillators ========= - Ichimoku, all lines under red expanding kumo - MACD turning down - DMI Neutral - StochRSI turning down, showing bearish signals ========= Conclusion ========= - Long term swing, price may reverse, to enter spot or wait for pullback.

1. RSI in oversold region 2. Price likely to rebound back the the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line)

1. RSI in oversold region 2. Price likely to rebound back the the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line)

Overview: Danaher Corporation (DHR) on the daily chart appears to have undergone a significant bearish pattern followed by a period of consolidation. The recent price action suggests a potential bullish reversal, as the stock has now broken above a key descending trendline, signaling a shift in momentum. Context & Price History: Prior Topping Pattern: From roughly February to April, DHR exhibited classic signs of a topping formation. The price repeatedly failed to break above the 210 to 215 Resistance zone (red shaded area), indicating strong supply in this region. The price action leading to the sharp April decline could be interpreted as a Head and Shoulders pattern or a triple top, with the white horizontal line around 196- 197 acting as a critical "neckline" or support level. Sharp Decline & Key Support: Following the breakdown from the neckline in April, DHR experienced a significant sell-off, finding strong demand and bottoming out within the 180 to 185 Key Level support zone (green shaded area). This zone has proven to be a robust area of buyer interest. Consolidation & Descending Trend: Since the April lows, DHR has been trading within a range, largely constrained by a descending trendline (thick red diagonal line) acting as dynamic resistance, while finding support at the 180-185 key level. This price action formed a descending triangle or wedge-like pattern. Key Levels & Patterns: Major Resistance (210 to 215): A strong supply zone where sellers have repeatedly stepped in. This will be the primary upside target if the current bullish momentum sustains. Key Support (180 to 185): A critical demand zone that has held up well, providing a strong foundation for the recent recovery. Descending Trendline (Red): This dynamic resistance has capped rallies since March/April. A decisive break above it is a bullish signal. Pivotal Level (~196-197, White Line): This level acted as prior support (neckline) before the April drop. Now, it serves as a minor horizontal resistance that the price has recently overcome, potentially flipping to support on a retest. Current Situation (As of Analysis): DHR is currently trading around $200. Critically, the price has made a strong move above the long-standing descending trendline. This breakout suggests that bullish sentiment is gaining control after a prolonged period of consolidation. Potential Scenarios: Bullish Continuation (Primary Indication on Chart): Confirmation: The chart's projection anticipates a retest of the broken descending trendline (which now acts as support) or the ~ 196=197 pivotal level, followed by a bounce and continuation higher. First Target: Upon a successful retest and bounce, the immediate target for buyers would be the 210 to 215 Resistance zone. Why: A confirmed breakout from a multi-month descending trendline, especially after holding strong key support, is a strong bullish reversal signal. Bearish Rejection / Fakeout: Confirmation: If DHR fails to hold above the broken descending trendline and closes convincingly back below it (and potentially below the ~196-197 level), it would suggest that the breakout was a "fakeout." Downside Potential: In such a scenario, the price could re-enter the consolidation range and potentially retest the 180 to 185 Key Level. Confirmation & Invalidations: Bullish Confirmation: A successful retest of the descending trendline (now support) with a clear bounce, or a sustained daily close above the ~196-197 level, preferably with increasing volume. Invalidation of Bullish Setup: A decisive daily close back below the descending trendline and the ~ 196-197 pivotal level would suggest that the bullish momentum has faltered and the current breakout might be false. Conclusion: DHR has presented a compelling technical setup with a breakout from a significant descending trendline. This breakout, combined with the stock holding firm at the 180-185 key support, suggests a potential shift in trend from bearish consolidation to a renewed bullish advance. Traders should look for confirmation of the breakout (e.g., a successful retest and bounce) before targeting the 210-215 resistance zone. Disclaimer: The information provided in this chart is for educational and informational purposes only and should not be considered as investment advice. Trading and investing involve substantial risk and are not suitable for every investor. You should carefully consider your financial situation and consult with a financial advisor before making any investment decisions. The creator of this chart does not guarantee any specific outcome or profit and is not responsible for any losses incurred as a result of using this information. Past performance is not indicative of future results. Use this information at your own risk. This chart has been created for my own improvement in Trading and Investment Analysis. Please do your own analysis before any investments.

We are close to the price low since 2020 now. This may seen as an important support. But the momentumis still high enough so that it may take time to build a bottom here. Before a major attempt to correct upward the lows at around 190 will likely be tested.